Newtown, Pa.-based Helius said it plans to use the proceeds from the 6.6-million-share flotation to complete a trial of the PoNS therapy in treating mild to moderate brain injury and the launch of a new trial in multiple sclerosis and another in cognition. The proceeds are also earmarked for R&D to complete an FDA submission, the company said.
Last year Helius closed an $8.1 million round. Last week, the company touted results from a pilot study in MS showing that patients treated with the PoNS device showed significant improvement in sensory organization tests, with functional-MRI scans showing significant blood oxygen level-dependent signal changes in the left primary motor cortex.
($1 = C$1.30514)
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.